PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:US20220112182A1
公开(公告)日:2022-04-14
Invented are compounds of Formula I
and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
本发明提供了I式化合物及其药学上可接受的盐类、酯类和前药,这些化合物是DGAT2抑制剂。同时,本发明提供了制备I式化合物的方法、含有I式化合物的制药组合物,以及使用这些化合物治疗肝脏脂肪变性、非酒精性脂肪性肝炎(NASH)、纤维化、2型糖尿病、肥胖症、高脂血症、高胆固醇血症、动脉硬化、认知下降、痴呆、心肾疾病如慢性肾脏疾病和心力衰竭等相关疾病和病症的方法,包括向需要治疗的患者投与I式化合物。